The concentrations of(24R)-24, 25(OHhD 3J, [25(OH)D 3J and its 3-sulphate [25(OH)D 33SJ in the plasma of healthy subjects, patients with chronic renal failure, patients with climacteric syndrome, pregnant women and foetuses were determined using the enzyme-linked immunosorbent assay and high-performance liquid chromatography. 25(OH)D 33S was not detected in about one-third of the plasma samples from patients with chronic renal failure (n = 26). The three metabolites in maternal plasma reached the highest levels in the second trimester ofpregnancy followed by a decrease to the values obtained in the first trimester. Older healthy women (age range 44-71 years) showed higherlevels of 24,25(OHhD 3 and 25(OH)D 3 in the plasma than did young healthy women (age range 21-29 years), whereas no clear difference was observed between the older healthy women and patients with climacteric syndrome. The level of25(OH)D 33S in the plasma was higher in the latter patients than in healthy women.
It is well-known that vitamin D 3 (D 3) is hydroxylated in the liver to give 25-hydroxyvitamin D 3 [25(OH)D 3J in the first step of its conversion to lrx,25-dihydroxyvitamin D 3 [lrx,25(OHhD 3J, which is the active metabolite in the intestine and bones, and that 25(OH)D 3 and its 3-sulphate [25(OH)D 33SJ circulate as the major metabolites of D 3 in the plasma. The concentration of 25(OH)D 3 in plasma is widely used for assessing the D 3 status in humans. For the determination of 25(OH)D 3, several methods have been developed using high-performance liquid chromatography (HPLC), but they are not very convenient because of the use of radioactive internal standard.' 25(OH)D 33S in plasma has also been measured by Axelson? and our group;' but its physiological significance remains to be clarified. (24R)-24,25-Dihydroxyvitamin D 3 [24,25(OHhD 3J is another major Correspondence: Dr Kazutake Shimada. metabolite of D 3 produced from 25(OH)D 3 by further stereospecific hydroxylation in the D-supplemented state ( Fig. 1 ). Although it is still controversial whether this metabolite plays a physiological role, its specific actions in bone 4 ,5 or cartilages have been reported. These findings prompted a search for the possible utility of this compound as a novel drug for diseases causing bone atrophy, and a specific and sensitive method of determining its level in serum/plasma became required. In these circumstances, we developed methods for 25(OH)D 3 and 25(OH)D 33S determination using HPLC,I,3 and a sensitive enzymelinked immunosorbent assay (ELISA) for 24,25(OHhD 3 determination."
In this report, we describe the application of these methods to the determination of 24,25(OHhD 3, 25(OH)D 3 and 25(OH)D 33S levels in plasma, and present data on comparison of healthy subjects, patients with chronic renal failure or climacteric syndrome, pregnant women and foetuses. Chemicals, samples and analytical methods 24,25(OHhD 3 and 25(OH)D 3 were supplied by Chugai Pharmaceutical Co. (Tokyo, Japan) and Teikoku Hormone Mfg. (Tokyo, Japan), respectively. 25(OH)D 33S was synthesized in our laboratory by a known method.! All other reagents and solvents were of analytical reagent grade as used in our previous studies.l-V' Blood was collected from the subjects into heparinized tubes and centrifuged at 1000g for 15 min at 4°C. The plasma was stored at -20°C until use. The measurement of plasma 24,25(OHhD 3 concentration was done with ELISA.7 2S(OH)D] and 25(OH)D 33S concentrations were measured by HPLC. I , 3 These methods were recently developed in our laboratory.
RESULTS

Statistical analyses
Results were evaluated by Student's t-test, and a P value of less than 0·05 was taken as significant. For samples with less than 5 nmol/L of 2S(OH)D) and 2S(OH)D]3S, which was the detection limit of the assays.t-' zero was placed in calculation of the mean. 
Levels of D 3 metabolites in healthy subjects
Our first effort was the determination of 24,2S(OH)2D], 2S(OH)D] and 2S(OH)D)3S in healthy subjects (men, n = 20; women, n = 36) and the following results were obtained: 24,2S(OH)2D), 3·63 (± 1'61) nrnol/L [mean (± 1 SD)]; 25(OH)D], 42·5 (± 18,0) nmol/L; 25(OH)D 33S, 37,1 (± lO'l)nmol/L (Fig. 2 ). These are compatible with results previously reported.s? The correlation y=7'16Ix+6'157
Structures of vitamin D, metabolites.
MATERIALS AND METHODS
Subjects/patients
A total of 56 samples were obtained from healthy volunteers: 36 women (age range 21-71 years) and 20 men (age range 22-54 years) known not to have received vitamin D therapy. Twenty-six samples were obtained from patients with chronic renal failure (CRF) (age range 30-79 years) whose serum concentrations of blood urea nitrogen and creatinine exceeded 1000 mg/L and 710 nmol/L, respectively. Seventeen samples were from patients with climacteric syndrome (age range 43--68 years), eleven of whom were treated with hormone replacement therapy (HRT), and 42 samples were from pregnant women (age range 25-38 years: first trimester, n= 11; second trimester, n=9; third trimester, n = 14; at delivery, n = 8). (r=0'671) was obtained for 25(OH)D] (y) and 24,25(OHhD] (x). A sex difference was not observed, but the 24,25(OHhD] and 25(OH)D] levels in the plasma of older healthy women (n= 13, age range 44-71 years) were higher than those in young healthy women (n = 23, age range 21-29 years (see Table 1 ).
Levels of D] metabolites in patients with chronic renal failure
The concentrations of the three metabolites of D] in the plasma of patients with CRF (men and women, each n = 13) were: 24,25(OHhD], 1·03 (±0.58) nmol/L; 25(OH)D], 27·3 (± 11-4)nmol/L; 25(OH)D]3S, 13-7 (± 13·1)nmol/L. These were significantly lower than results in healthy subjects (Fig. 2) . The values of 24,25(OHhD] and 25(OH)D] are compatible with those previously reported. 10 ,1I We could not detect 25(OH)D]3S in nine plasma samples, that is, in more than one-third of all specimens examined. None of the three metabolite levels was influenced by the administration of l zhydroxyvitamin D], which is used for treating renal osteodystrophy; results [administered (n = 13) vs not administered (n = 13)] were: 24,25(OHhD], 1·01 (± 0-41) vs 1·06 (± O'72) nmol/ L; 25(OH)D], 26·3 (±9'35) vs 28·3 (± l3-5)nmol/L; 25(OH)D]3S, 17·7 (± 11,5) vs 9-69 (± 13.8)nmol/L,
Levels of D] metabolites in maternal and foetal plasma
The concentration of the three metabolites in maternal plasma was measured and compared with the data obtained from young healthy women (n = 23, age range 21-29 years).
Although the concentration of the three metabolites in maternal plasma scattered over the normal range, the highest value was observed in the second trimester (14-27 weeks) of pregnancy, followed by a decrease to the value obtained at the first trimester (less than 14 weeks). The average value of 25(OH)D] [52,8 (± 15'5)nmol/L] in the second trimester was significantly higher than that in young healthy women, at P = 0·0064 (Fig. 3 ). Since no difference was observed between the plasma samples from an artery and a vein of the umbilical cord, the averaged values are shown for the foetal plasma (Fig. 3) . The plasma obtained from the artery or vein of the umbilical cord showed lower 25(OH)D] values (~1/2) than for maternal plasma, while a higher value of 25(OH)D]3S was obtained with the umbilical cord plasma. This observation IS III agreement with previously reported results. 12,13
Levels of D 3 metabolites in patients with climacteric syndrome The plasma of patients with climacteric syndrome, some of whom were receiving HRT containing oestrogen, were examined for the three metabolites of D 3 (see Table I ), The concentration of 25(OH)D 33S was significantly higher in the patients than in young healthy women. Although the P value was 0'055, the same tendency was observed when compared with older healthy women. In contrast, no clear difference was observed in plasma concentrations of 24,25(OHhD 3 and 25(OH)D 3 between the climacteric syndrome patients and older healthy women.
DISCUSSION
The concentrations of the three metabolites of D 3 we found in the plasma of healthy subjects were within the range of those previously reported. 2.9 , l0 The levels of 24,25(OHhD 3 in patients with CRF were significantly lower than those of healthy subjects, which was in agreement with others' reports.P'!' Although 25(OH)D 3 is produced in the liver, not the kidney, its level in CRF patients was as low as that in a previous report, 10, 11 This result may be explained by the fact that 25(OH)D 3 bound to a D-binding protein easily leaks into the urine, as do other proteins, in CRF. The levels of 25(OH)D 3 and 25(OH)D 33S in the umbilical cord plasma were lower and higher, respectively, than those in the maternal plasma samples reported previously.Fi'?
We found in this study that 25(OH)D 33S was not detectable in about one-third of the plasma samples from patients with CRF. We noted that the three metabolites of D 3 showed the highest levels in the maternal plasma in the second trimester of pregnancy. The plasma levels of 24,25(OH)2D3 and 25(OH)D 3 in older healthy women were higher than those in young healthy women. This finding differed from previous reports that the levels of these metabolites were independent of age. 14 , 15 Although a significant difference was not observed in the plasma levels of 24,25(OH)2D3 and 25(OH)D 3 between older healthy women and patients with climacteric syndrome, the level of 25(OH)D 33S in the climacteric syndrome patients was higher than that in older or young healthy women. This may Ann cu« Biochem 1999: 36
give a clue to the relation between vitamin D metabolism and climacteric syndrome. It has been reported that the plasma concentration of liX,25(OHhD but not of 25(OH)D is increased by administration of oestrogen," and we found that the changes in plasma concentrations of 24,25(OHhD 3 and 25(OH)D 33S under the conditions of oestrogen administration were not observed in patients with climacteric syndrome.
All these data show that our methods of 24,25(OH)2D3, 25(OH)D 3 and 25(OH)D 33S determination using ELISA and HPLC are useful for determination and study of these metabolites in human plasma. Further studies on these metabolites in other biological fluids using these methods will clarify the physiological significance of 24,25(OH)2D3 and 25(OH)D 33S.
